About BioDelivery Sciences International (NASDAQ:BDSI)
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. has a licensing and development agreement with Evonik Corporation and Meda AB. The company was founded in 1997 and is headquartered in Raleigh, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:BDSI
CUSIP09060J10
Phone919-582-9050
Debt
Debt-to-Equity Ratio5.37%
Current Ratio1.52%
Quick Ratio1.29%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$61.99 million
Price / Sales2.05
Cash FlowN/A
Price / CashN/A
Book Value$0.16 per share
Price / Book13.56
Profitability
EPS (Most Recent Fiscal Year)($0.39)
Net Income$5.28 million
Net Margins8.52%
Return on Equity22.93%
Return on Assets5.54%
Miscellaneous
Employees116
Outstanding Shares58,450,000
BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions
What is BioDelivery Sciences International's stock symbol?
BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."
How were BioDelivery Sciences International's earnings last quarter?
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) posted its quarterly earnings results on Thursday, March, 15th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.05. The specialty pharmaceutical company earned $12.51 million during the quarter, compared to analyst estimates of $9.83 million. BioDelivery Sciences International had a return on equity of 22.93% and a net margin of 8.52%. View BioDelivery Sciences International's Earnings History.
When is BioDelivery Sciences International's next earnings date?
What price target have analysts set for BDSI?
7 equities research analysts have issued 1-year price objectives for BioDelivery Sciences International's stock. Their forecasts range from $4.00 to $5.00. On average, they anticipate BioDelivery Sciences International's share price to reach $4.4286 in the next twelve months. View Analyst Ratings for BioDelivery Sciences International.
What are Wall Street analysts saying about BioDelivery Sciences International stock?
Here are some recent quotes from research analysts about BioDelivery Sciences International stock:
- 1. Cantor Fitzgerald analysts commented, "Positives from the quarter: 1) BDSI announced it had secured preferred coverage for Belbuca with Humana (HUM, Neutral) effective March 1. Effective Jan. 1, 2018, United Healthcare (UNH, OW) removed step edits for Belbuca, and CVS/Caremark (CVS, Not covered) and ProCareRx moved Belbuca to a preferred position. Additionally, Belbuca and Butrans have been added to the Ohio Workers Comp formulary as preferred medications, effective 4/1/18; 2) Belbuca prescriptions grew 10% in 4Q17 vs. 3Q17, and have continued to grow in 2018; 3) Scott Plesha was appointed to the role of President; and 4) cash and equivalents totaled $21.9MM at 12/31/17, which should fund operations into 2H18. Management noted on the call that it could potentially qualify for an additional tranche of its loan agreement in 2018. Other levers the company has to decrease cash burn and extend the cash runway include better-than- expected sales, lower R&D and SG&A spending, and potential partnerships or divestments of the company’s other products." (3/15/2018)
- 2. According to Zacks Investment Research, "BioDelivery has secured improved positioning in six new managed care contracts providing preferred access to its key drug, Bunavail, since July 2016. This is expected to boost the drug’s sales and profitability in turn. Meanwhile, its second marketed drug, Belbuca, recently received an approval in Canada for severe pain that should support further sales growth. BioDelivery’s shares have significantly outperformed the industry in the last one year. However, the company suffered a setback with the discontinuation of clonidine topical gel for management of painful diabetic neuropathy in December 2016. BioDelivery’s portfolio as well as its pipeline candidates may also face a severe competition as it targets a highly genericized and crowded market." (2/14/2018)
Who are some of BioDelivery Sciences International's key competitors?
Some companies that are related to BioDelivery Sciences International include StemlineTherapeutics (STML), Akebia Therapeutics (AKBA), Insys Therapeutics (INSY), Progenics Pharmaceuticals (PGNX), Achillion Pharmaceuticals (ACHN), ObsEva (OBSV), CannTrust (CNTTF), Innate Pharma (IPHYF), MediciNova (MNOV), Zealand Pharma (ZEAL), Isotechnika Pharma (AUPH), ProMetic Life Sciences (PFSCF), Sinovac Biotech (SVA), Concert Pharmaceuticals (CNCE) and Synergy Pharmaceuticals (SGYP).
Who are BioDelivery Sciences International's key executives?
BioDelivery Sciences International's management team includes the folowing people:
- Dr. Francis E. O'Donnell Jr., M.D., Exec. Chairman (Age 68)
- Dr. Mark A. Sirgo, Vice Chairman & Interim CEO (Age 64)
- Mr. Ernest Robert De Paolantonio CPA, MBA, CFO, Corp. Sec. & Treasurer (Age 65)
- Dr. Niraj Vasisht, CTO & Sr. VP of Product Devel. (Age 54)
- Mr. Scott M. Plesha, Pres
Has BioDelivery Sciences International been receiving favorable news coverage?
Media stories about BDSI stock have been trending somewhat positive on Tuesday, according to Accern. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioDelivery Sciences International earned a daily sentiment score of 0.09 on Accern's scale. They also assigned media headlines about the specialty pharmaceutical company an impact score of 45.38 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are BioDelivery Sciences International's major shareholders?
BioDelivery Sciences International's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BROADFIN CAPITAL, LLC (7.30%). Company insiders that own BioDelivery Sciences International stock include Barry I Feinberg, Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht, Paolantonio Ernest Robert De, Samuel P Sears, Jr and William B Stone. View Institutional Ownership Trends for BioDelivery Sciences International.
How do I buy shares of BioDelivery Sciences International?
Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioDelivery Sciences International's stock price today?
One share of BDSI stock can currently be purchased for approximately $2.17.
How big of a company is BioDelivery Sciences International?
BioDelivery Sciences International has a market capitalization of $131.51 million and generates $61.99 million in revenue each year. The specialty pharmaceutical company earns $5.28 million in net income (profit) each year or ($0.39) on an earnings per share basis. BioDelivery Sciences International employs 116 workers across the globe.
How can I contact BioDelivery Sciences International?
BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]
MarketBeat Community Rating for BioDelivery Sciences International (BDSI)
MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote "Outperform" if you believe BDSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
BioDelivery Sciences International (NASDAQ:BDSI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for BioDelivery Sciences International in the last 12 months. Their average twelve-month price target is $4.4286, suggesting that the stock has a possible upside of 104.08%. The high price target for BDSI is $5.00 and the low price target for BDSI is $4.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.86 | 2.86 | 2.83 | 2.83 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.4286 | $4.4286 | $4.50 | $4.50 |
| Price Target Upside: | 104.08% upside | 123.67% upside | 91.49% upside | 52.54% upside |
BioDelivery Sciences International (NASDAQ:BDSI) Consensus Price Target History
BioDelivery Sciences International (NASDAQ:BDSI) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
BioDelivery Sciences International (NASDAQ:BDSI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
BioDelivery Sciences International (NASDAQ BDSI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.73%
Institutional Ownership Percentage: 44.16%
BioDelivery Sciences International (NASDAQ BDSI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/10/2018 | Mark A Sirgo | Director | Sell | 100,000 | $2.06 | $206,000.00 | 2,585,966 |  |
| 4/6/2018 | Paolantonio Ernest Robert De | CFO | Sell | 64,155 | $2.09 | $134,083.95 | 97,731 | |
| 3/8/2018 | Francis E Odonnell Jr | Director | Sell | 113,876 | $2.14 | $243,694.64 | 319,717 | |
| 1/19/2018 | Mark A Sirgo | Director | Sell | 709,502 | $2.73 | $1,936,940.46 | 1,759,262 | |
| 1/17/2018 | Mark A Sirgo | Director | Sell | 108,000 | $2.57 | $277,560.00 | 1,759,262 | |
| 1/3/2018 | Mark A Sirgo | Director | Sell | 162,509 | $2.78 | $451,775.02 | 1,759,262 | |
| 9/21/2017 | Mark A Sirgo | Insider | Sell | 201,373 | $2.84 | $571,899.32 | 1,509,262 | |
| 9/20/2017 | Mark A Sirgo | CEO | Sell | 65,405 | $2.75 | $179,863.75 | 1,509,262 | |
| 9/19/2017 | Mark A Sirgo | CEO | Sell | 24,516 | $2.75 | $67,419.00 | 1,509,262 | |
| 9/18/2017 | Mark A Sirgo | CEO | Sell | 6,000 | $2.85 | $17,100.00 | 1,509,262 | |
| 9/15/2017 | Mark A Sirgo | CEO | Sell | 54,833 | $2.90 | $159,015.70 | 1,509,262 | |
| 9/14/2017 | Mark A Sirgo | CEO | Sell | 50,000 | $2.95 | $147,500.00 | 1,509,262 | |
| 3/31/2017 | Mark A Sirgo | CEO | Sell | 110,895 | $1.90 | $210,700.50 | 1,670,157 | |
| 3/23/2017 | Francis E Odonnell Jr | Director | Sell | 750 | $1.90 | $1,425.00 | 272,049 | |
| 3/23/2017 | Niraj Vasisht | SVP | Sell | 530 | $1.90 | $1,007.00 | 272,943 | |
| 3/23/2017 | Paolantonio Ernest Robert De | CFO | Sell | 170 | $1.90 | $323.00 | 96,634 | |
| 1/30/2017 | Niraj Vasisht | Insider | Sell | 6,905 | $1.91 | $13,188.55 | 178,727 | |
| 12/1/2016 | Samuel P. Sears, Jr. | Director | Sell | 12,000 | $1.67 | $20,040.00 | | |
| 11/23/2016 | Barry I Feinberg | Director | Buy | 2,000 | $1.67 | $3,340.00 | | |
| 11/17/2016 | Barry I Feinberg | Director | Buy | 3,000 | $1.87 | $5,610.00 | | |
| 9/23/2016 | Francis E Odonnell Jr | Director | Sell | 100,000 | $2.57 | $257,000.00 | | |
| 9/23/2016 | Niraj Vasisht | Insider | Sell | 47,000 | $2.43 | $114,210.00 | 73,081 | |
| 9/22/2016 | Paolantonio Ernest Robert De | CFO | Sell | 14,800 | $2.44 | $36,112.00 | 14,866 | |
| 8/25/2016 | Barry I Feinberg | Director | Buy | 2,500 | $2.55 | $6,375.00 | | |
| 8/11/2016 | William B Stone | Director | Sell | 16,000 | $2.57 | $41,120.00 | 122,675 | |
| 3/21/2016 | Charles Bramlage | Director | Buy | 8,850 | $2.82 | $24,957.00 | 28,150 | |
| 3/18/2016 | Barry I Feinberg | Director | Buy | 10,000 | $2.74 | $27,400.00 | | |
| 3/18/2016 | Niraj Vasisht | CTO | Buy | 1,000 | $2.80 | $2,800.00 | 68,420 | |
| 3/17/2016 | Paolantonio Ernest Robert De | CFO | Buy | 4,000 | $2.60 | $10,400.00 | 13,383 | |
| 11/24/2015 | Francis E Odonnell Jr | Director | Sell | 50,000 | $6.01 | $300,500.00 | | |
| 11/13/2015 | Thomas D'alonzo | Director | Buy | 4,528 | $5.52 | $24,994.56 | 76,379 | |
| 9/3/2015 | Francis E Odonnell Jr | Director | Sell | 20,000 | $6.43 | $128,600.00 | 144,671 | |
| 8/26/2015 | Paolantonio Ernest Robert De | CFO | Buy | 1,650 | $6.20 | $10,230.00 | 9,383 | |
| 8/13/2015 | William B Stone | Director | Sell | 11,500 | $7.01 | $80,615.00 | | |
| 6/16/2015 | Francis E Odonnell Jr | Director | Sell | 21,597 | $8.03 | $173,423.91 | | |
| 6/16/2015 | Mark A Sirgo | CEO | Sell | 4,187 | $7.97 | $33,370.39 | | |
| 5/26/2015 | Barry I Feinberg | Director | Buy | 2,000 | $7.84 | $15,680.00 | | |
| 5/14/2015 | Barry I Feinberg | Director | Buy | 2,000 | $8.54 | $17,080.00 | | |
| 5/13/2015 | Thomas D'alonzo | Director | Buy | 6,226 | $8.07 | $50,243.82 | | |
| 12/26/2014 | Francis E Odonnell Jr | Director | Sell | 70,000 | $12.00 | $840,000.00 | | |
| 12/15/2014 | Mark A Sirgo | CEO | Buy | 2,500 | $12.23 | $30,575.00 | | |
| 12/10/2014 | Samuel P Sears Jr | Director | Sell | 7,853 | $15.03 | $118,030.59 | | |
| 11/12/2014 | William B Stone | Director | Sell | 14,000 | $16.11 | $225,540.00 | | |
| 9/4/2014 | Barry I Feinberg | Director | Buy | 1,000 | $15.18 | $15,180.00 | | |
| 9/4/2014 | Mark A Sirgo | CEO | Buy | 2,000 | $15.04 | $30,080.00 | | |
| 8/27/2014 | Andrew L Finn | EVP | Sell | 90,000 | $15.00 | $1,350,000.00 | | |
| 8/22/2014 | Charles Bramlage | Director | Buy | 1,800 | $13.85 | $24,930.00 | | |
| 6/25/2014 | Paolantonio Ernest Robert De | CFO | Buy | 1,250 | $12.13 | $15,162.50 | | |
| 6/12/2014 | Samuel P Sears Jr | Director | Sell | 5,000 | $12.33 | $61,650.00 | | |
| 6/11/2014 | Francis E Odonnell Jr | Director | Sell | 125,000 | $11.04 | $1,380,000.00 | | |
| 3/26/2014 | Francis Odonnell, Jr. | Director | Sell | 50,000 | $8.04 | $402,000.00 | | |
| 3/20/2014 | Samuel Sears, Jr. | Director | Sell | 4,000 | $9.00 | $36,000.00 | 19,853 | |
| 3/11/2014 | Andrew Finn | EVP | Sell | 80,000 | $9.99 | $799,200.00 | 660,450 | |
| 3/11/2014 | William Stone | Director | Sell | 35,000 | $10.00 | $350,000.00 | 63,178 | |
| 2/20/2014 | Andrew Finn | EVP | Sell | 18,737 | $8.84 | $165,635.08 | 740,450 | |
| 2/20/2014 | Francis Odonnell, Jr. | Director | Sell | 70,000 | $8.92 | $624,400.00 | 2,521,751 | |
| 2/20/2014 | Mark Sirgo | CEO | Sell | 42,000 | $8.92 | $374,640.00 | 913,250 | |
| 1/24/2014 | Andrew Finn | EVP | Sell | 143,679 | $9.03 | $1,297,421.37 | 705,653 | |
| 1/24/2014 | James Mcnulty | SVP | Sell | 89,223 | $8.73 | $778,916.79 | 49,399 | |
| 1/24/2014 | John Shea | Director | Sell | 130,000 | $8.78 | $1,141,400.00 | 13,305 | |
| 1/24/2014 | Mark Sirgo | CEO | Sell | 116,253 | $9.01 | $1,047,439.53 | 815,250 | |
| 11/18/2013 | Mark Sirgo | CEO | Buy | 2,337 | $4.29 | $10,025.73 | 874,179 | |
| 9/19/2013 | Francis Odonnell, Jr. | Director | Sell | 95,000 | $5.36 | $509,200.00 | 3,121,751 | |
| 9/11/2013 | Samuel P Sears Jr | Director | Sell | 2,000 | $5.37 | $10,740.00 | | |
| 9/9/2013 | Samuel P Sears Jr | Director | Sell | 7,500 | $5.05 | $37,875.00 | | |
| 8/26/2013 | Andrew Finn | EVP | Buy | 5,000 | $4.58 | $22,900.00 | 775,653 | |
| 8/16/2013 | Mark Sirgo | CEO | Buy | 5,100 | $4.43 | $22,593.00 | 871,842 | |
| 8/15/2013 | William Stone | Director | Sell | 6,825 | $4.44 | $30,303.00 | 63,175 | |
| 8/14/2013 | James Mcnulty | CFO | Buy | 5,000 | $4.50 | $22,500.00 | 49,399 | |
| 6/21/2013 | Mark A Sirgo | CEO | Buy | 3,400 | $4.30 | $14,620.00 | | |
| 6/20/2013 | Francis E Odonnell Jr | Director | Sell | 72,689 | $4.36 | $316,924.04 | | |
| 6/5/2013 | Samuel P Sears Jr | Director | Sell | 5,000 | $4.42 | $22,100.00 | | |
| 12/21/2012 | Andrew L Finn | EVP | Buy | 3,000 | $3.85 | $11,550.00 | | |
| 12/21/2012 | Mark A Sirgo | CEO | Buy | 4,975 | $4.02 | $19,999.50 | | |
(Data available from 1/1/2013 forward)
BioDelivery Sciences International (NASDAQ BDSI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | BioDelivery Sciences International, Inc. (BDSI) Expected to Announce Quarterly Sales of $10.77 Million
www.americanbankingnews.com - April 21 at 2:52 AM |
| Brokerages Expect BioDelivery Sciences International, Inc. (BDSI) to Post -$0.23 Earnings Per Share
www.americanbankingnews.com - April 19 at 3:10 PM |
 | Recent Analysis Shows J.Jill, BankUnited, Toronto Dominion Bank, Adamis Pharmaceuticals, BioDelivery Sciences International, and First Solar Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - April 19 at 9:30 AM |
| BioDelivery Sciences International (BDSI) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - April 18 at 7:30 PM |
| Q1 2018 Earnings Estimate for BioDelivery Sciences International, Inc. (BDSI) Issued By William Blair
www.americanbankingnews.com - April 18 at 7:58 AM |
| Why Is BioDelivery Sciences (BDSI) Up 2.4% Since Its Last Earnings Report?
finance.yahoo.com - April 16 at 9:34 AM |
| BioDelivery Sciences International, Inc. (BDSI) Director Mark A. Sirgo Sells 100,000 Shares
www.americanbankingnews.com - April 13 at 10:10 PM |
| BioDelivery Sciences International (BDSI) PT Set at $4.00 by HC Wainwright
www.americanbankingnews.com - April 13 at 2:17 PM |
| BioDelivery Sciences International (BDSI) Given a $5.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 10 at 11:38 PM |
 | BRIEF-Broadfin Capital Reports 7.3 Pct Stake In Biodelivery Sciences
www.reuters.com - April 10 at 9:28 AM |
| BioDelivery Sciences International, Inc. (BDSI) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 8 at 7:33 AM |
| Paolantonio Ernest Robert De Sells 64,155 Shares of BioDelivery Sciences International, Inc. (BDSI) Stock
www.americanbankingnews.com - April 6 at 7:33 PM |
| Analysts Expect BioDelivery Sciences International, Inc. (BDSI) Will Post Quarterly Sales of $11.04 Million
www.americanbankingnews.com - April 4 at 2:32 AM |
 | From BDSI to Red Hat: The Triangle's top inside stock sales of 1Q2018
www.bizjournals.com - April 3 at 9:11 AM |
| BioDelivery Sciences International, Inc. (BDSI) Expected to Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - April 2 at 5:16 PM |
| BioDelivery Sciences International, Inc. to Post Q1 2018 Earnings of ($0.23) Per Share, Seaport Global Securities Forecasts (BDSI)
www.americanbankingnews.com - March 26 at 1:06 AM |
| BioDelivery Sciences International, Inc. to Post FY2018 Earnings of ($0.70) Per Share, Cantor Fitzgerald Forecasts (BDSI)
www.americanbankingnews.com - March 23 at 10:56 AM |
 | BioDelivery Sciences (BDSI) in Focus: Stock Moves 5.1% Higher - Nasdaq
www.nasdaq.com - March 21 at 4:59 PM |
| Blog Exposure - Dova Pharma Inked Agreement with Fosun Pharma for Distribution of Avatrombopag in Mainland China and Hong Kong
finance.yahoo.com - March 21 at 9:45 AM |
| BioDelivery Sciences (BDSI) in Focus: Stock Moves 5.1% Higher
finance.yahoo.com - March 21 at 9:45 AM |
| BioDelivery Sciences International (BDSI) Given a $4.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 19 at 5:02 PM |
| William Blair Comments on BioDelivery Sciences International, Inc.'s Q1 2019 Earnings (BDSI)
www.americanbankingnews.com - March 19 at 6:46 AM |
| BioDelivery Sciences International, Inc. (BDSI) Expected to Post Quarterly Sales of $9.50 Million
www.americanbankingnews.com - March 18 at 4:07 AM |
| BioDelivery (BDSI) Q4 Loss Wider-Than-Expected, Sales Up Y/Y - Nasdaq
www.nasdaq.com - March 17 at 10:11 AM |
| BioDelivery (BDSI) Q4 Loss Wider-Than-Expected, Sales Up Y/Y
finance.yahoo.com - March 16 at 4:53 PM |
| Brokerages Anticipate BioDelivery Sciences International, Inc. (BDSI) to Announce -$0.25 EPS
www.americanbankingnews.com - March 16 at 3:21 PM |
 | BioDelivery Sciences International's (BDSI) CEO Mark Sirgo on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 16 at 10:02 AM |
| CORRECTING and REPLACING -- BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 16 at 10:02 AM |
| Edited Transcript of BDSI earnings conference call or presentation 15-Mar-18 8:30pm GMT
finance.yahoo.com - March 16 at 10:02 AM |
| Raleigh pharma quadruples revenue, lands new contract
finance.yahoo.com - March 16 at 10:02 AM |
| BioDelivery Sciences International (BDSI) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 16 at 8:52 AM |
| BioDelivery Sciences International's (BDSI) "Buy" Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - March 15 at 9:26 PM |
| BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 15 at 4:43 PM |
| What You Must Know About BioDelivery Sciences International Inc’s (NASDAQ:BDSI) ROE
finance.yahoo.com - March 15 at 10:17 AM |
 | BioDelivery Sciences to Present at the Oppenheimer 28th Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 14 at 12:14 PM |
| BioDelivery Sciences to Present at the Oppenheimer 28th Annual Healthcare Conference
finance.yahoo.com - March 14 at 12:14 PM |
| Francis E. Odonnell, Jr. Sells 113,876 Shares of BioDelivery Sciences International, Inc. (BDSI) Stock
www.americanbankingnews.com - March 9 at 6:32 PM |
| BioDelivery Sciences International (BDSI) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - March 8 at 1:11 AM |
| BioDelivery Sciences to Host Conference Call and Webcast Reporting Fourth Quarter and Full-Year 2017 Financial Results on Thursday, March 15
finance.yahoo.com - March 7 at 9:48 AM |
| BioDelivery Sciences International, Inc. (BDSI) Shares Sold by Stonepine Capital Management LLC
www.americanbankingnews.com - March 6 at 2:53 PM |
| BioDelivery Sciences to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 5 at 10:04 AM |
| BioDelivery Sciences International (BDSI) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - March 4 at 11:06 PM |
| Short Interest in BioDelivery Sciences International, Inc. (BDSI) Rises By 44.8%
www.americanbankingnews.com - March 3 at 3:26 AM |
| Broadfin Capital LLC Buys 223,253 Shares of BioDelivery Sciences International, Inc. (BDSI)
www.americanbankingnews.com - March 2 at 5:08 AM |
 | What's in the Cards for BioDelivery (BDSI) in Q4 Earnings?
www.msn.com - March 1 at 9:24 AM |
| What's in the Cards for BioDelivery (BDSI) in Q4 Earnings?
finance.yahoo.com - March 1 at 9:24 AM |
| Royce & Associates LP Grows Holdings in BioDelivery Sciences International, Inc. (BDSI)
www.americanbankingnews.com - March 1 at 8:24 AM |
| Brokerages Anticipate BioDelivery Sciences International, Inc. (BDSI) Will Post Quarterly Sales of $9.83 Million
www.americanbankingnews.com - March 1 at 4:34 AM |
| Zacks: Brokerages Expect BioDelivery Sciences International, Inc. (BDSI) to Post -$0.25 EPS
www.americanbankingnews.com - February 27 at 1:24 PM |
| BioDelivery Sciences International, Inc. (BDSI) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 17 at 8:46 AM |
BioDelivery Sciences International (NASDAQ:BDSI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
BioDelivery Sciences International (NASDAQ:BDSI) Income Statement, Balance Sheet and Cash Flow Statement
BioDelivery Sciences International (NASDAQ BDSI) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
